Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC.

Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17.

2.

Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality.

van Rijn RS, Simonetti ER, Hagenbeek A, Bonyhadi M, Storm G, Martens AC, Ebeling SB.

Exp Hematol. 2007 Jan;35(1):117-27.

PMID:
17198880
3.

Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.

Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB.

Clin Cancer Res. 2006 Sep 15;12(18):5520-5.

4.

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.

van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB.

Clin Cancer Res. 2006 Jul 1;12(13):4027-35.

5.
6.

T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.

Ivanov R, Hol S, Aarts TI, Hagenbeek A, Ebeling SB.

Clin Exp Immunol. 2006 Jan;143(1):78-84.

7.

Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious.

Ebeling SB, Simonetti ER, Borst HP, Blok A, Schelen AM, Braakman E, Ederveen J, Hagenbeek A.

Gene Ther. 2003 Oct;10(21):1800-6.

PMID:
12960969
8.

A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.

van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB.

Blood. 2003 Oct 1;102(7):2522-31. Epub 2003 Jun 5.

PMID:
12791667
9.

HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells.

Ebeling SB, Ivanov R, Hol S, Aarts TI, Hagenbeek A, Verdonck LF, Petersen EJ.

Br J Haematol. 2003 Jun;121(5):721-9.

PMID:
12780786
10.

Development and application of quantitative real time PCR and RT-PCR assays that discriminate between the full-length and truncated herpes simplex virus thymidine kinase gene.

Ebeling SB, Eric Borst HP, Simonetti ER, Hol S, Garin MI, Slaper-Cortenbach I, Hagenbeek A.

J Virol Methods. 2003 May;109(2):177-86.

PMID:
12711061
11.

Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells.

Taams LS, Vukmanovic-Stejic M, Smith J, Dunne PJ, Fletcher JM, Plunkett FJ, Ebeling SB, Lombardi G, Rustin MH, Bijlsma JW, Lafeber FP, Salmon M, Akbar AN.

Eur J Immunol. 2002 Jun;32(6):1621-30.

12.

Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas.

Ebeling SB, Bos HM, Slater R, Overkamp WJ, Cuthbert AP, Newbold RF, Zdzienicka MZ, Aarden LA.

Cancer Res. 1998 Jul 1;58(13):2863-8.

13.

Molecular analysis of VH regions expressed in the adult B-cell repertoire.

van der Stoep N, Ebeling SB, Logtenberg T.

Ann N Y Acad Sci. 1995 Sep 29;764:275-84. Review. No abstract available.

PMID:
7486536
14.

Leucine-58 in the putative 5th helical region of human interleukin (IL)-6 is important for activation of the IL-6 signal transducer, gp130.

de Hon FD, Klaasse Bos HK, Ebeling SB, Grötzinger J, Kurapkat G, Rose-John S, Aarden LA, Brakenhoff JP.

FEBS Lett. 1995 Aug 7;369(2-3):187-91.

15.

Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.

de Hon FD, Ehlers M, Rose-John S, Ebeling SB, Bos HK, Aarden LA, Brakenhoff JP.

J Exp Med. 1994 Dec 1;180(6):2395-400.

16.

Peripheral human CD5+ and CD5- B cells may express somatically mutated VH5- and VH6-encoded IgM receptors.

Ebeling SB, Schutte ME, Logtenberg T.

J Immunol. 1993 Dec 15;151(12):6891-9.

PMID:
7505018
18.

The majority of human tonsillar CD5+ B cells express somatically mutated V kappa 4 genes.

Ebeling SB, Schutte ME, Logtenberg T.

Eur J Immunol. 1993 Jun;23(6):1405-8.

PMID:
7684690
19.
20.

Molecular approaches to the study of human B-cell and (auto)antibody repertoire generation and selection.

Logtenberg T, Schutte ME, Ebeling SB, Gmelig-Meyling FH, van Es JH.

Immunol Rev. 1992 Aug;128:23-47. Review.

PMID:
1330894
21.

Expression of members of the immunoglobulin VH3 gene families is not restricted at the level of individual genes in human chronic lymphocytic leukemia.

Ebeling SB, Schutte ME, Akkermans-Koolhaas KE, Bloem AC, Gmelig-Meyling FH, Logtenberg T.

Int Immunol. 1992 Mar;4(3):313-20.

PMID:
1567789
22.

Sequence analysis of small subunit ribosomal RNA genes and its use for detection and identification of Leishmania parasites.

van Eys GJ, Schoone GJ, Kroon NC, Ebeling SB.

Mol Biochem Parasitol. 1992 Mar;51(1):133-42.

PMID:
1565128
23.

Antibody specificity and immunoglobulin VH gene utilization of human monoclonal CD5+ B cell lines.

Schutte ME, Ebeling SB, Akkermans KE, Gmelig-Meyling FH, Logtenberg T.

Eur J Immunol. 1991 May;21(5):1115-21.

PMID:
1709863
24.

Immunoglobulin variable gene expression in human autoantibodies.

van Es JH, Schutte ME, Ebeling SB, Gmelig-Meyling FH, Logtenberg T.

Immunol Ser. 1991;55:119-31. Review. No abstract available.

PMID:
1720024
25.

Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis.

Schalken JA, Ebeling SB, Isaacs JT, Treiger B, Bussemakers MJ, de Jong ME, Van de Ven WJ.

Cancer Res. 1988 Apr 15;48(8):2042-6.

Supplemental Content

Loading ...
Support Center